In 1993, Johnson & Johnson owned schizophrenia. That multimillion segment of the antipsychotic market had long been an untapped income source, populated by old-school generics that came with their fair share of side effects. But now J&J, through its subsidiary Janssen Pharmaceuticals, blew the doors off the market with its…